ACCC Launches New Public Policy Website

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 1
Volume 11
Issue 1

ROCKVILLE, Maryland-The Association of Community Cancer Centers (ACCC) has launched a new website (www.accc-cancer.org/publicpolicy) dedicated to regulatory and legislative issues affecting patients with cancer. The website will assist in the education of patients and their families about public policy that affects cancer care.

ROCKVILLE, Maryland—The Association of Community Cancer Centers (ACCC) has launched a new website (www.accc-cancer.org/publicpolicy) dedicated to regulatory and legislative issues affecting patients with cancer. The website will assist in the education of patients and their families about public policy that affects cancer care.

The new website also was designed to serve as a tool to bring patients and physicians together to discuss important cancer issues, such as new therapeutic modalities, insurance reimbursement, and clinical trials. The public policy site features information for patients and their families regarding access to cancer care, and details on oral cancer drugs and the congressional actions affecting use of such drugs.

The site features a section on legislative alerts, general information about Capitol Hill legislators, and tips for patients with cancer and their families on communicating with their representatives. The site also provides a directory of ACCC member hospitals and physicians, a list of patient advocacy organizations, and contact information for representatives and senators.

"By providing patients and families with information about the public policies that impact cancer care and helping them learn about the legislative process, they will be able to fully act on their rights and enlist the government in their personal battles against cancer," said Margaret A. Riley, MN, RN, of ACCC’s Ad Hoc Committee for Advocacy. 

Recent Videos
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content